Goals and Background: Hepatitis C virus (HCV) is a hepatotropic and lymphotropic virus. This agent can promote development of a panel of autoimmune diseases. The relationship between HCV infection and vitiligo, in which autoimmune mechanisms are believed to play a role is not yet elucidated. In this study we investigated HCV seropositivity in vitiligo patients and compared this with non vitiligo population. Study: A total of 102 consecutive patients with vitiligo were included in the study (47 male, 55 female, mean age: 36.8±16.9 years, range: 5-75). Control population was 670 age and sex matched healthy blood donors (406 male, 264 female, mean age: 32.8±11.3 years, range: 20-58). Third generation enzyme immunoassay was used for serum anti HCV determination. When positive, qualitative confirmation was performed by HCV RNA determination using RT PCR. Results: Anti HCV antibody was detected only in 1 patient and confirmed by RT PCR test. This patient was a 6-year old girl with a nonsegmental form of vitiligo, which is more frequently associated with autoimmune disorders, hence the incidence of HCV seropositivity found as 0.98%. There was no statistically significant difference between this figure and 0.6%prevalence in healthy blood donors. Conclusion: Seroprevalence of HCV in vitiligo patients is not different from that of a control group in Turkey; and HCV infection may not be involved in the pathogenesis of vitiligo despite case reports showing co existence of these 2 diseases. Goals and Background: Hepatitis C virus (HCV) is a hepatotropic and lymphotropic virus. This agent can promote development of a panel of autoimmune diseases. The relationship between HCV infection and vitiligo, in which autoimmune mechanisms are believed to play a role is not yet elucidated. In this study we investigated HCV seropositivity in vitiligo patients and than this with non vitiligo population. Study: A total of 102 consecutive patients with vitiligo were included in the study (47 male, 55 female, mean age: 36.8 ± 16.9 years, range: 5-75). Control population was 670 age and sex matched healthy blood donors (406 male, 264 female, mean age: 32.8 ± 11.3 years, range: 20-58). Third generation enzyme immunoassay was used for serum anti HCV determination. When positive, identification confirmation was performed by HCV RNA determination using RT PCR. Results: Anti HCV antibody was detected only in 1 patient and confirmed by RT PCR test. This patient was a 6-year old girl with a nonseg mental form of vitiligo, which is more frequently associated with autoimmune disorders, hence the incidence of HCV seropositivity found as 0.98%. There was no significant significant between between this figure and 0.6% prevalence in healthy blood donors. Conclusion: Seroprevalence of HCV in vitiligo patients is not different from that of a control group in Turkey; and HCV infection may not be involved in the pathogenesis of vitiligo despite case reports co existence of these 2 diseases.